Triiodothyronine for the treatment of critically ill patients with COVID-19 infection (Thy-Support Study)
Phase 1
- Conditions
- ICU patients diagnosed with pulmonary infection due to COVID-19 and require mechanical respiratory support or ECMOTherapeutic area: Diseases [C] - Virus Diseases [C02]MedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestations
- Registration Number
- EUCTR2020-001623-13-GR
- Lead Sponsor
- ni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
•Patients diagnosed with pulmonary infection due to COVID-19, admitted
in ICU and require mechanical ventilation or ECMO
•Male and female with Age>18 years old
•Signed informed consent from patient or relatives
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 20
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 40
Exclusion Criteria
•Pregnant or breast-feeding women
•Severe systemic disease (e.g. cancer) before infection accompanied by reduced life expectancy <6 months
•Participation in another trial of an investigational drug or device
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method